Abilify: America’s Once Best-Selling Drug Now Offers a Classic Tale of Big Pharma Greed
What do you do if your pharmaceutical drug lacks a clear competitive advantage and is connected to a long list of side effects? If you are Bristol-Myers Squibb with its Abilify, you spend millions on consumer and physician advertising, stay silent about the drug’s risks, and trump up its benefits. This is Abilify’s story, a